Limitations: Although here we investigated many novel aspects (age, sex) of NASH development, testing therapeutic interventions (e.g., PCSK9 inhibitors, IL-1β neutralizing antibodies), using knock-out animals, and following the time course of disease development was out of the scope of our study. The gene discussed is IL1B; the disease is metabolic dysfunction-associated steatohepatitis.